Surgical Science Sweden AB (publ) (STO:SUS)

Market Cap	2.53B -45.2%
Revenue (ttm)	1.02B +8.4%
Net Income	93.14M +0.7%
EPS	1.82 +0.6%
Shares Out	51.03M
PE Ratio	27.26
Forward PE	18.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,498
Open	48.64
Previous Close	49.62
Day's Range	48.12 - 49.62
52-Week Range	23.70 - 94.70
Beta	0.66
Analysts	Strong Buy
Price Target	65.40 (+34.02%)
Earnings Date	Nov 12, 2026

About STO:SUS

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnosti...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 319
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SUS

Financial Performance

In 2025, STO:SUS's revenue was 992.34 million, an increase of 12.25% compared to the previous year's 884.09 million. Earnings were 66.82 million, a decrease of -49.24%.

Analyst Summary

According to 4 analysts, the average rating for SUS stock is "Strong Buy." The 12-month stock price target is kr 65.40, which is an increase of 34.02% from the latest price.

Price Target

kr 65.40

(34.02% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error